Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Theriva Biologics财年每股收益美元（1.14美元）超过预期（1.28美元）；截至2023年12月31日，Theriva Biologics公布了2320万美元的现金，预计将为2025年第一季度提供资金
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.28) by 10.94 percent. This is a 12.98 percent increase over losses of $(1.31) per share from the same period last year.
Theriva Biologics（美国证券交易所股票代码：TOVX）公布的季度亏损为每股1.14美元，比分析师共识估计的美元（1.28美元）高出10.94％。与去年同期每股亏损1.31美元（1.31）相比，增长了12.98％。